Recommendations of Others
The ADA acknowledged that data from prospective studies were insufficient to determine the benefits of diabetes screening and thus concluded that the decision to test for diabetes should be based on clinical judgment and patient preference.66 On the basis of expert consensus, the ADA recommends clinicians consider screening for diabetes with the FPG test beginning at age 45 years and at a younger age for individuals with such risk factors as family history, overweight, and hypertension, among others. The American College of Obstetricians and Gynecologists endorses the ADA recommendations.67 The American Heart Association recommends measuring fasting blood glucose in persons 20 years of age and older according to patient's risk for diabetes, as part of overall risk assessment for cardiovascular disease.68 The Canadian Task Force on Preventive Health Care is currently updating its recommendations on diabetes screening.
Return to Contents
References
1. United States Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. Alexandria, VA: Office of Disease Prevention and Health Promotion; 1996.
2. Harris R, Donahue K, Rathore S, Frame P, Woolf S, Lohr KN. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003;138:215-290.
3. Harris R, Lux L, Bunton A, et al. Screening for Type 2 Diabetes Mellitus: Systematic Evidence Review No. 19 (Prepared by Research Triangle Institute—University of North Carolina Evidence-based Practice Center under Contract No. 290-97-0017). Rockville, MD. Agency for Healthcare Research and Quality. May 2002 (Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat3.chapter.3895).
4. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-524.
5. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24:1936-40.
6. Moss SE, Klein R, Klein BE. The incidence of vision loss in a diabetic population. Ophthalmology 1988;95(10):1340-8.
7. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997;20(5):725-734.
8. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20(5):735-744.
9. Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon WM, Palumbo PJ. Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. Ann Intern Med 1989;111(10):788-796.
10. Resnick HE, Valsania P, Phillips CL. Diabetes mellitus and nontraumatic lower extremity amputation in black and white Americans: The National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, 1971-1992. Arch Intern Med 1999;159:2470-275.
11. Humphrey LL, Palumbo PJ, Butters MA, et al. The contribution of non-insulin-dependent diabetes to lower-extremity amputation in the community. Arch Intern Med 1994;154:885-892.
12. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-853.
13. Moss SE, Klein R, Klein BE. The 14-year incidence of lower-extremity amputations in a diabetic population. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 1999;22(6):951-959.
14. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998;21:296-309.
15. McCance DR, Hanson RL, Charles MA, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 1994;308(6940):1323-1328.
16. Engelgau MM, Thompson TJ, Herman WH, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. Diabetes Care 1997;20:785-791.
17. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
18. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-240.
19. Engelgau MM, Thompson TJ, Smith PJ, et al. Screening for diabetes mellitus in adults. The utility of random capillary blood glucose measurements. Diabetes Care 1995;18(4):463-466.
20. Harwell TS, Smilie JG, McDowall JM, Helgerson SD, Gohdes D. Diabetes screening practices among individuals aged 45 years and older. Diabetes Care 2000;23(1):125-126.
21. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
22. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-5130.
23. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-544.
24. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
25. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 6: complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 1990;13:1-11.
26. Kohner EM, Aldington SJ, Stratton IM, et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 1998;116(3):297-303.
27. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
28. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993 118(2):129-138.
29. Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. Cochrane Database Systematic Review 2001;1:CD002183.
30. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplantation 1995;10(11):1963-1974.
31. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997;20(10):1576-1581.
32. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
33. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
34. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870-878.
35. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998 128(12 Pt 1):982-988.
36. Fogari R, Zoppi A, Corradi L, et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type 2 diabetes and impaired renal function. J Human Hyperten 1999;13(1):47-53.
37. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):145-153.
38. Mason J, O'Keeffe C, McIntosh A, Booth A, Young RJ. A systematic review of foot ulcer in patients with Type 2 diabetes mellitus: prevention. Diabet Med 1999;16:801-812.
39. Malone JM, Snyder M, Anderson G, Bernhard VM, Holloway GAJ, Bunt TJ. Prevention of amputation by diabetic education. Am J Surg 1989;158:520-523.
40. Litzelman DK, Slemenda CW, Langefeld CD, et al. Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1993 119:36-41.
41. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762.
42. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996;276(23):1886-1892.
43. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999;340(9):677-684.
44. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
45. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels:subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661-2667.
46. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
47. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-418.
48. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22.
49. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the u.s. Preventive services task force. Ann Intern Med 2002;136(2):161-72.
50. Colwell JA. Aspirin therapy in diabetes. Diabetes Care 1997;20:1767-71.
51. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2000;23:S61-S62.
52. Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ. Impact of diabetes screening on quality of life. Diabetes Care 2002;25(6):1022-6.
53. Eriksson KE, Lindgarde F. Impaired glucose tolerance in a middle-aged male urban population: a whole new approach for identifying high-risk cases. Diabetologia 1990;33:526-531.
54. Yudkin JS, Alberti KGMM, McLarty DG, Swai ABM. Impaired glucose tolerance: is it a risk factor for diabetes or a diagnostic ragbag? BMJ 1990;301:397-401.
55. Balkau B, Eschwege E. Repeatability of the oral glucose tolerance test for the diagnosis of impaired glucose tolerance and diabetes mellitus. Diabetologia 1991;34:201-202.
56. Ramaiya KL, Swai ABM, McLarty DG, Kitange HM, Alberti KGMM. Improvement in glucose tolerance after one year of follow-up in a Hindu community in Africa. Diabet Res Clin Pract 1990;10:245-255.
57. Swai ABM, McLarty DG, Kitange HM, et al. Study in Tanzania of impaired glucose tolerance: methodological myth? Diabetes 1991;40:516-520.
58. Bourn DM, Williams SM, Mann JI. Distinguishing between persistent and transient impaired glucose tolerance using a prediction model. Diabet Med 1992;9:744-748.
59. Warram JH, Sigal RJ, Martin BC, Krolewski AS, Soeldner JS. Natural history of impaired glucose tolerance: follow-up at Joslin Clinic. Diabet Med 1996;13:S40-S45.
60. Israili ZH, Wall WD. Cough and angioneurotic edema associated with angiotensin-converting-enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992;117:234-242.
61. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264:71-75.
62. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol 1994;74:667-73.
63. Testa MA, Simonson DC, Turner RR. Valuing quality of life and improvements in glycemic control in people with type 2 diabetes. Diabetes Care 1998;21 Suppl 3:C44-52.
64. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 1998 280:1490-1496.
65. UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999;22:1125-1136.
66. Screening for Diabetes. Diabetes Care. American Diabetes Association 2002;25(90001):S21-S24.
67. American College of Obstetricians and Gynecologists. Guidelines for Women's Health Care. 2nd Edition. Washington DC; American Coll of Obstetricians and Gynecologists; 2002:210-213.
68. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106(3):388-91.
Return to Contents
Members of the Task Force
Members of the U.S. Preventive Services Task Force are Alfred O. Berg, M.D., M.P.H., Chair, USPSTF (Professor and Chair, Department of Family Medicine, University of Washington, Seattle, WA); Janet D. Allan, Ph.D., R.N., Vice-chair, USPSTF (Dean, School of Nursing, University of Maryland Baltimore, Baltimore, MD); Paul Frame, M.D. (Tri-County Family Medicine, Cohocton, NY, and Clinical Professor of Family Medicine, University of Rochester, Rochester, NY); *Charles J. Homer, M.D., M.P.H. (Executive Director, National Initiative for Children's Healthcare Quality, Boston, MA); Mark S. Johnson, M.D., M.P.H. (Professor of Family Medicine, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, NJ); Jonathan D. Klein, M.D., M.P.H. (Associate Professor, Department of Pediatrics, University of Rochester School of Medicine, Rochester, NY); *Tracy A. Lieu, M.D., M.P.H. (Associate Professor, Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School, Boston, MA); C. Tracy Orleans, Ph.D. (Senior Scientist and Senior Program Officer, The Robert Wood Johnson Foundation, Princeton, NJ); *Jeffrey F. Peipert, M.D., M.P.H. (Director of Research, Women and Infants' Hospital, Providence, RI); *Nola J. Pender, Ph.D., R.N., (Professor Emeritus, University of Michigan, Ann Arbor, MI); Albert L. Siu, M.D., M.S.P.H (Professor of Medicine, Chief of Division of General Internal Medicine, Mount Sinai School of Medicine, New York, NY); Steven M. Teutsch, M.D., M.P.H. (Senior Director, Outcomes Research and Management, Merck & Company, Inc., West Point, PA); Carolyn Westhoff, M.D., M.Sc. (Professor of Obstetrics and Gynecology and Professor of Public Health, Columbia University, New York, NY); and Steven H. Woolf, M.D., M.P.H. (Professor, Department of Family Practice and Department of Preventive and Community Medicine and Director of Research Department of Family Practice, Virginia Commonwealth University, Fairfax, VA).
*Member of the Task Force at the time this recommendation was finalized.
Return to Contents
Contact the Task Force
Address correspondence to: Chair, U.S. Preventive Services Task Force; c/o Project Director, USPSTF; 540 Gaither Road; Rockville, MD 20850; E-mail: info@ahrq.gov.
Return to Contents
Available Products
This recommendation
and rationale statement, plus complete information on which this statement
is based, including evidence tables and references, are available on the USPSTF
Web site at http://www.preventiveservices.ahrq.gov.
Recommendations made by the USPSTF are independent of the U.S. Government. They should not be construed as an official position of AHRQ or the U.S. Department of Health and Human Services.
Source: This recommendation first appeared in Ann Intern Med 2003;138(3):212-4.
Return to Contents
Current as of February 2003
Internet Citation:
U.S. Preventive Services Task Force. Screening for Type 2 Diabetes Mellitus in Adults: Recommendations and Rationale. February 2003. Agency for Healthcare
Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/3rduspstf/diabscr/diabetrr.htm
540 Gaither Road Rockville, MD 20850